Overview

3 Month PHI PAD PoM Study

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, blinded, placebo controlled study to evaluate the safety of GSK1278863 and its acute and short-term (e.g. 14d) effects on calf muscle endurance and walking ability in subjects with PAD and symptomatic claudication.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline